Scientists today must deliver breakthroughs in technically challenging fields with flat budgets. Our assay technology is designed to help you do more with less. Built on innovation and rooted in sound research methods developed by the Imperiali Laboratory at MIT, our technologies are patented and exclusively licensed to AssayQuant. We leverage our extensive assay development expertise to offer robust products that enable the breakthrough discoveries and increased productivity that will improve human health while fitting within your budget.
Our product portfolio using the Sulfonamido-oxine (Sox) fluorophore for detection of protein kinase and phosphatase activity is commercialized under the brand name PhosphoSens. Sox was designed to be small and minimally hydrophobic and is well-tolerated across diverse sequences and targets.
By harnessing chelation-enhanced fluorescence (ChEF) with improved sulfonamido-oxine (Sox) chromophore technology for peptide or protein substrates, we have created a simple yet powerful method to measure the activity of protein kinases or phosphatases using a direct and homogeneous format that provides more information with less effort and accomodates any ATP concentration or sample type. The continuous (kinetic) format is ideal for elucidating drug mechanism of action, potency and profiling, while the Endpoint/Red format is ideal for HTS and SAR. One can switch between formats with the same sensor, to provide seamless coverage across the entire discovery and drug development process. For additional information, see slides to the right or Click here for our Technotes Capabilities description.
AssayQuant has created a robust, high-throughput process for generating superior and fit-for-purpose Sox-based substrates starting with a physiologically relevant or known substrate. Our approach integrates the improved CSox technology from the Imperiali laboratory that allows flanking sequence on either side of the Sox chromophore. These optimized CSox substrates can be used in kinetic or endpoint assays. We have designed both highly generic and highly selective sensors.
The PhosphoSens platform delivers flexibility with assay components (use a wide range of ATP, substrate, activators or inhibitors), assay volume, plate configurations (96, 384 or 1536-well), microplate readers and sample types (purified enzyme or crude lysate) – all with a simple to use (add & read) and highly quantitative format that we offer in 3 variations:
The kinetic format captures the complete progress curve (fluorescence intensity over time) for every condition and with no additional handling. The endpoint format can use a stop solution to allow processing of plates in batch mode to provide higher-throughput.
Most of the 30-plus commercially available kinase assay platforms use antibodies, coupled reactions, indirect measurements, radioactivity or complex instrumentation for detection. These and other limitations have slowed progress and prevented scientific discovery. Our recent advancements in continuous protein kinase or phosphatase activity assays accelerate discovery by providing better information with reduced effort.
Better technology doesn't have to be more expensive. We understand the need to deliver a solution that is faster, better and cost-effective. Our exclusive PhosphoSens platform is unmatched in terms of simplicity, speed, cost and quality of information.
If you're looking to improve productivity with less work and more value, contact AssayQuant today.